Fougera(R) Announces First Generic Approval of Imiquimod Cream 5% (Rx), Equivalent to Aldara(R)
MELVILLE, N.Y., Feb. 25 /PRNewswire/ -- E. Fougera & Co., a leading specialty pharmaceutical manufacturer, today announced it has received first generic approval from the FDA for Imiquimod Cream 5% (Rx). Fougera's Imiquimod Cream 5% is rated AB, generically equivalent to Aldara® by Graceway Pharmaceuticals and substitutable for all indications. According to industry data, U.S. sales of the brand named product in 2009 exceed $360 million.
"Fougera's commitment to develop this high profile, first-to-market product as a cost-effective generic provides healthcare professionals the ability to prescribe a more affordable treatment, thereby making it accessible to more patients," said David Klaum, Sr. Vice President and General Manager of Fougera.
Full Prescribing Information and Patient Information for Imiquimod Cream 5% are available at www.fougera.com or can be requested by calling (800) 645-9833.
Founded in 1849, Fougera is a division of Nycomed US Inc. and is the leading manufacturer and distributor of a wide range of topical products. For more information on Fougera's complete line of products, please call Fougera Customer Service at (800) 645-9833 or visit the company online at www.fougera.com.
About Nycomed US Inc.
Nycomed US Inc. is a subsidiary of Nycomed. In addition to Fougera, Nycomed US Inc. operates two additional divisions of specialty pharmaceuticals. The PharmaDerm division is dedicated to developing and commercializing novel prescription products to treat diseases and conditions of the skin—the largest organ of the human body. Nycomed US Inc. also markets and sells Savage Laboratories products, which focus on emergency care. More information is available at www.nycomedus.com.